Identification of Actual 10-Year Survival After Hepatectomy of HBV-Related Hepatocellular Carcinoma: a Multicenter Study
- 130 Downloads
Hepatitis B virus (HBV) infection is the leading cause of hepatocellular carcinoma (HCC) worldwide. The aim of the study was to identify the incidence and predictive factors of actual 10-year survival following liver resection of HBV-related HCC.
A Chinese multicenter database of patients undergoing curative hepatectomy of HBV-related HCC was reviewed. Patients who survived ≥ 10 years and patients who died < 10 years after surgery were compared and analyzed. Univariable and multivariable regression analyses were performed to identify predictive factors associated with 10-year survival.
Among all enrolled 1016 patients, the actuarial 10-year survival rate was 24.1%, while the actual 10-year survival rate was 16.6%. There were 169 patients who survived at least 10 years after surgery and 688 who died within 10 years from surgery. These patients constituted the study population of this study. Multivariable regression analysis revealed that cirrhosis, preoperative HBV viral load > 104 copies/mL, maximum tumor size > 5 cm, multiple tumors, macroscopic and microscopic vascular invasion, postoperative HBV reactivation, and early recurrence (< 2 years after surgery) were independent risk factors associated with actual 10-year survival, while postoperative antiviral therapy, regular recurrence surveillance, and curative treatments for initial recurrence were independent protective factors.
The actual 10-year survival after curative resection of HBV-related HCC was calculated to be 16.6%. Postoperative antiviral therapy and regular recurrence surveillance were independent protective factors associated with actual 10-year survival after liver resection of HBV-related HCC.
KeywordsHepatocellular carcinoma Hepatectomy Overall survival Hepatitis B virus
Hepatitis B virus
Hepatitis C virus
Body mass index
American Society of Anesthesiologists
Magnetic resonance imaging
Transcatheter arterial chemoembolization
- 95% CI
95% confidence interval
This work was supported in part by the National Natural Science Foundation of China (No. 81472284 and 81672699) and Shanghai Pujiang Program (No. 16PJD004).
Conception: Tian Yang, Feng Shen; study design: Tian Yang, Zhen-Li Li, Wen-Tao Yan, Jin Zhang, Xian-Hai Mao, Hao Xing, Jun Han; administrative support: Meng-Chao Wu, Feng Shen; data collection and acquisition: Chao Li, Ming-Da Wang, Ya-Hao Zhou, Ting-Hao Chen, Wei-Min Gu, Hong Wang, Yong-Yi Zeng; data analysis: Zhen-Li Li, Yi-Jun Zhao, Jun Han, Han Wu, Tian Yang; manuscript preparation: Zhen-Li Li, Wen-Tao Yan, Jin Zhang, Yi-Jun Zhao, Xian-Hai Mao, Tian Yang; critical revision: Feng Shen, Tian Yang, Wan Yee Lau; final approval of manuscript: all authors.
Compliance with Ethical Standards
Informed consent for the data to be used for clinical researches was obtained from all enrolled patients. This study was performed in accordance with the Declaration of Helsinki and the Ethical Guidelines for Clinical Studies of all the seven enrolled hospitals.
Conflict of Interest
The authors declare that they have no conflicts of interest.
- 2.Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 2015, 385:117–171.Google Scholar
- 5.Yang T, Lu JH, Zhai J, Lin C, Yang GS, Zhao RH, Shen F, Wu MC. High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study. Eur J Surg Oncol, 2012, 38:683–691.CrossRefGoogle Scholar
- 13.Vitale A, Burra P, Frigo AC, Trevisani F, Farinati F, Spolverato G, Volk M, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di MM, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Gasbarrini A, Sacco R, Foschi FG, Missale G, Morisco F, Svegliati BG, Virdone R, Cillo U. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. J Hepatol, 2015, 62:617–624.CrossRefGoogle Scholar
- 14.Yang T, Lu JH, Lau WY, Zhang TY, Zhang H, Shen YN, Alshebeeb K, Wu MC, Schwartz M, Shen F. Perioperative blood transfusion does not influence recurrence-free and overall survivals after curative resection for hepatocellular carcinoma: a Propensity Score Matching Analysis. J Hepatol, 2016, 64:583–593.CrossRefGoogle Scholar
- 15.Hyun MH, Lee YS, Kim JH, Lee CU, Jung YK, Seo YS, Yim HJ, Yeon JE, Byun KS. Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: a meta-analysis of high-quality studies. Hepatology, 2018. DOI: https://doi.org/10.1002/hep.29883.
- 26.Huang G, Li PP, Lau WY, Pan ZY, Zhao LH, Wang ZG, Wang MC, Zhou WP. Antiviral therapy reduces hepatocellular carcinoma recurrence in patients with low HBV-DNA levels: a randomized controlled trial. Ann Surg, 2018. DOI: https://doi.org/10.1097/SLA.0000000000002727.
- 29.Yamamoto Y, Ikoma H, Morimura R, Konishi H, Murayama Y, Komatsu S, Shiozaki A, Kuriu Y, Kubota T, Nakanishi M, Ichikawa D, Fujiwara H, Okamoto K, Sakakura C, Ochiai T, Otsuji E. Optimal duration of the early and late recurrence of hepatocellular carcinoma after hepatectomy. World J Gastroenterol, 2015, 21:1207–1215.CrossRefGoogle Scholar
- 32.Zheng J, Chou JF, Gönen M, Vachharajani N, Chapman WC, Majella DMB, Turcotte S, Vandenbroucke-Menu F, Lapointe R, Buettner S, Groot KB, JNM I, Chan CY, BKP G, Teo JY, Kam JH, Jeyaraj PR, Cheow PC, AYF C, PKH C, LLPJ O, Balachandran VP, Kingham TP, Allen PJ, D’Angelica MI, DeMatteo RP, Jarnagin WR, Lee SY. Prediction of hepatocellular carcinoma recurrence beyond Milan criteria after resection: validation of a clinical risk score in an international cohort. Ann Surg, 2017, 266:693–701.CrossRefGoogle Scholar
- 38.Bagante F, Spolverato G, Weiss M, Alexandrescu S, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultsides GA, Soubrane O, Martel G, Groot KB, Guglielmi A, Itaru E, Pawlik TM. Defining long-term survivors following resection of intrahepatic cholangiocarcinoma. J Gastrointest Surg, 2017, 21:1888–1897CrossRefGoogle Scholar
- 40.Tran TB, Postlewait LM, Maithel SK, Prescott JD, Wang TS, Glenn J, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC, Kiernan CM, Votanopoulos KI, Levine EA, Hatzaras I, Shenoy R, Pawlik TM, Norton JA, Poultsides GA. Actual 10-year survivors following resection of adrenocortical carcinoma. J Surg Oncol, 2016, 114:971–976.CrossRefGoogle Scholar
- 41.Creasy JM, Sadot E, Koerkamp BG, Chou JF, Gonen M, Kemeny NE, Balachandran VP, Kingham TP, DeMatteo RP, Allen PJ, Blumgart LH, Jarnagin WR, D’Angelica MI. Actual 10-year survival after hepatic resection of colorectal liver metastases: what factors preclude cure. Surgery, 2018, 163:1238–1244.CrossRefGoogle Scholar